Image Sourced Dorsavi Limited
Market Herald logo


Be the first with the news that moves the market

ASM Technologies has signed a three-year contract with dorsaVi for 64 myViSafe kits.

ViSafe are wearable movement sensors which collect video and motion data, pinpointing unsafe work practices which may lead to serious injury.

This technology can be used to assess movement repetition, muscle activity and, challenging postures.

It can also be used in a range of workplaces from health care, hospitality, construction and, retail.

“The ViSafe study has proven to be a practical and essential tool to assess work activities, deciding on the purchase of developing plant and equipment for the future,” Sean Watters, Emergency Response Unit Manager said.

ASM Technologies will be using these kits to support self-managing handling risks and facilitating changes in manual handling.

These kits cost a total of $550k and delivery is expected to begin rolling out later in the year.

CEO of dorsaVi Dr. Andrew Ronchi is excited for his product to begin being used in workplaces.

“This is our largest rollout of myViSafe to a single organisation to date and I’m delighted to see myViSafe being incorporated into this large-scale workplace safety program,” he said.

Please find announcement attached here:

DVL by the numbers
More From The Market Herald

" Epsilon Healthcare (ASX:EPN) extends agreement with The Valens Company

Epsilon Healthcare (EPN) has extended its agreement with The Valens Company to January 31, 2022.
Starpharma (ASX:SPL)

" Starpharma’s (ASX:SPL) nasal spray registered for sale in Vietnam

Starpharma’s (SPL) VIRALEZE product has been registered for sale in Vietnam.  
Telix Pharmaceuticals (ASX:TLX) - CEO, Christian Behrenbruch

" Telix Pharmaceuticals’ (ASX:TLX) Illuccix authorised in Brazil

Telix Pharmaceuticals (TLX) has been granted authorisation for Illuccix, the company’s lead prostate cancer imaging product.
PharmAust (ASX:PAA) - Chief Scientific Officer, Richard Mollard

" PharmAust (ASX:PAA) successfully produces smaller GMP tablets

PharmAust’s (PAA) upcoming human trials have received a major boost as the company’s GMP monepantel (MPL) tablets has been produced at a smaller